Chugai Pharmaceutical Co., Ltd.
4519
Classifica tra le azioni
#350
Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company,... Chugai Pharmaceutical Co., Ltd. is a prominent global pharmaceutical company, operating subsidiaries involved in the full lifecycle of drug development, from research and manufacturing to sales, import, and export, serving both Japanese and international markets. Its commercialized product portfolio spans several key therapeutic areas. These include a robust oncology offering with leading treatments like Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda. Additionally, it provides medications for bone health (e.g., Actemra, Edirol, Bonviva), renal conditions (such as Mircera and Oxarol), and neurological or other diverse ailments (including Hemlibra, CellCept, and Enspryng). Beyond its existing offerings, the company maintains an active research and development pipeline. This pipeline features multiple promising candidates targeting oncology, orthopedic and joint disorders, autoimmune diseases, kidney-related conditions, and various neurological or other health issues. Strategic partnerships are central to Chugai's operations, most notably a significant alliance with the Roche Group. The company also fosters collaborative research initiatives with academic institutions. Established in 1925, Chugai's headquarters are located in Tokyo, Japan, and it operates as a key subsidiary of Roche Holding Ltd.
Prezzo delle azioni
$41.60
Capitalizzazione di mercato
$68.46B
Variazione (1 giorno)
0.94%
Variazione (1 anno)
-12.56%
Paese
JP
Scambia Chugai Pharmaceutical Co., Ltd. (4519)
Categoria
Healthcare
Utile per Chugai Pharmaceutical Co., Ltd. (4519)
Utile nel 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Chugai Pharmaceutical Co., Ltd., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, uguale a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Chugai Pharmaceutical Co., Ltd. dal 2003 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2025 | $3.81B | 10.18% |
| 2024 | $3.46B | 9.91% |
| 2023 | $3.15B | -22.32% |
| 2022 | $4.05B | 11.19% |
| 2021 | $3.64B | 26.14% |
| 2020 | $2.89B | 51.00% |
| 2019 | $1.91B | 72.67% |
| 2018 | $1.11B | 28.63% |
| 2017 | $861.20M | 35.29% |
| 2016 | $636.58M | -12.20% |
| 2015 | $725.04M | 14.00% |
| 2014 | $635.98M | -12.96% |
| 2013 | $730.71M | -13.05% |
| 2012 | $840.36M | 13.52% |
| 2011 | $740.25M | -8.49% |
| 2010 | $808.92M | -16.02% |
| 2009 | $963.18M | 38.51% |
| 2008 | $695.38M | 17.04% |
| 2007 | $594.11M | 12.26% |
| 2006 | $529.22M | -27.64% |
| 2005 | $731.36M | 30.51% |
| 2004 | $560.37M | 21.93% |
| 2003 | $459.59M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $33.60B | - |
US
|
|
| $17.74B | - |
US
|
|
| $8.70B | - |
US
|
|
| $5.95B | - |
US
|
|
| $21.39B | - |
CH
|
